715 related articles for article (PubMed ID: 29521236)
1. In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.
Lemos A; Melo R; Preto AJ; Almeida JG; Moreira IS; Dias Soeiro Cordeiro MN
Curr Neuropharmacol; 2018; 16(6):786-848. PubMed ID: 29521236
[TBL] [Abstract][Full Text] [Related]
2. Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
Jones-Tabah J
J Mol Biol; 2023 Jun; 435(12):167927. PubMed ID: 36563742
[TBL] [Abstract][Full Text] [Related]
3. Non-dopaminergic treatments for motor control in Parkinson's disease.
Fox SH
Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
[TBL] [Abstract][Full Text] [Related]
4. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
5. Glutamate receptors as therapeutic targets for Parkinson's disease.
Johnson KA; Conn PJ; Niswender CM
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
[TBL] [Abstract][Full Text] [Related]
6. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
Luthra PM; Kumar JB
Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
[TBL] [Abstract][Full Text] [Related]
7. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
[TBL] [Abstract][Full Text] [Related]
8. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in the pharmacological treatment of Parkinson's disease.
Tuite P; Riss J
Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
[TBL] [Abstract][Full Text] [Related]
10. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Jones CK; Bubser M; Thompson AD; Dickerson JW; Turle-Lorenzo N; Amalric M; Blobaum AL; Bridges TM; Morrison RD; Jadhav S; Engers DW; Italiano K; Bode J; Daniels JS; Lindsley CW; Hopkins CR; Conn PJ; Niswender CM
J Pharmacol Exp Ther; 2012 Feb; 340(2):404-21. PubMed ID: 22088953
[TBL] [Abstract][Full Text] [Related]
11. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
12. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Simms SL; Huettner DP; Kortagere S
Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
[TBL] [Abstract][Full Text] [Related]
13. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
14. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
Sebastianutto I; Cenci MA
Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
[TBL] [Abstract][Full Text] [Related]
15. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
Maranis S; Tsouli S; Konitsiotis S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
[TBL] [Abstract][Full Text] [Related]
16. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
17. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
Radad K; Gille G; Rausch WD
Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacotherapy of Parkinson's disease: progress or regress?].
Pytka K; Zygmunt M; Filipek B
Postepy Hig Med Dosw (Online); 2013 Jul; 67():700-8. PubMed ID: 24018435
[TBL] [Abstract][Full Text] [Related]
19. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease : what's on the horizon?
Wu SS; Frucht SJ
CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
